New strategies applied In the treatment of experimental autoimmune disease models Involve blocking or modulation of MHC-peptide-TCR Interactions either at the level of peptide-MHC interaction or, alternatively, at the level of T cell recognition. In order to Identify useful competitor peptldes one must be able to assess peptide-MHC Interactions. Several well described autoimmune disease models exist In the Lewis rat and thus this particular rat strain provides a good model system to study the effect of competitor peptldes. So far no Information has been available on the peptide binding characteristics of the Lewis rat MHC class II RT1.B 1 molecule. We have now developed a biochemical binding assay which enables competition studies In which the relative MHC binding affinity of a set of non-labelled peptldes can be assessed while employing detection of blotlnylated marker peptides by chemllumlnescence. The assay Is sensitive and specific. We have used this assay to determine the binding characteristics of several disease associated T cell determinants and their sequence analogues In the Lewis rat. Notably, most of the autoimmune disease associated peptide sequences tested were found to be Intermediate to poor binders. Single amino acid substitutions at defined positions were sufficient to turn certain peptldes Into good binders. These results are relevant to the design of competitor peptldes In the treatment of experimental autoimmune diseases.
Introduction
A novel approach in the treatment of CD4 + T cell mediated experimental autoimmune diseases involves the inhibition or modulation of T cell responses by interfering with the formation of the trimolecular complex formed by MHC class II molecules, processed antigen (peptide) and TCR, by employing so-called competitor peptides. The formation of this trimolecular complex is an essential part of the final antigen-specific event in CD4 to have a far more limited, albeit more specific, effect. In any event, to work a competitor peptide needs to engage the MHC molecule in question.
The role of autoaggressive CD4 + T cells in several experimental autoimmune disease models is evident, since T cell clones both in mice and in rats have been isolated which can transfer the disease into naive recipient animals (10, 11, 12) . In the peptide induced experimental autoimmune encephalomyelitis (EAE) model in rodents, the use of competitor peptides already has proven successful in prevention of the disease (13) (14) (15) (16) . The Lewis rat is an inbred rat strain particularly prone to autoimmune diseases such as adjuvant arthritis (AA) (17) , EAE (18) , experimental autoimmune uveoretinitis (EAU) (19) and experimental autoimmune myasthenia gravis (EAMG) (20) . Most disease associated CD4 + T cell responses have so far been found to be restricted to a single MHC class II molecule, RT1 .B' (20) (21) (22) (23) (24) (25) . The Lewis rat is therefore a good model system to study the ffect of competitor peptides. However, no biochemical assay exists to determine the interaction between peptide and RT1 .B', or any other rat MHC class II molecule. It has therefore not been possible to ascertain the affinity of RT1.B 1 for any autoimmune disease related peptides or for any other peptide.
Consequently, we have developed a non-radioactive MHC class II-peptide binding assay which will allow us to rapidly screen peptides for their capacity to bind to the RT1.B 1 molecule. To establish the assay we made use of an already well defined MHC -peptide combination [the binding of peptides hen egg lysozyme (H EL) 107-116 and dynorphin (DYN) 1 -13 to purifed E d molecules (26) ], and we then used the new assay to describe a new MHC specificity, i.e. RT1 .B 1 . To our knowledge the direct binding of immunogenic peptides to RT1.0 is the first reported in the rat. It enabled us to define the relative RT1.B 1 binding capacity of autoimmune disease related T cell epitopes and their analogues. These results are of relevance to the design of MHC class II binding competitor peptides.
Methods

Peptides
Peptides used in the study were:
For the Lewis (30) . Peptide IRBP 1181-1191 was synthesized using t-BOC chemistry on an Applied Biosystems (Forster City, CA) Model 430A peptide synthesizer. The remaining peptides were synthesized by automated simultaneous multiple peptide synthesis (31) . The peptides were purified by HPLC and subsequently checked by fast atom bombardment mass spectrometry.
7" cell lines and clones
T cell clone 1 /C11 .P7 with specificity for OVA 323 -339 belongs to a series of RT1.B 1 restricted OVA-specific T cell clones (B. Stier etal., unpublished data). Briefly, Lewis rats were immunized with a total of 40 /ig of OVA emulsified in physiologic saline and complete Freund's adjuvant, injecting 100 /tl of emulsion per hind footpad. Ten days later cells from the draining lymph nodes were passed through nylon wool and were cultured at 2x10* cells/ml in Iscove's modified Dulbecco's medium supplemented with 2 mM L-glutamine, 5x 10~5 M 2-mercaptcethanol, 100 IU penicillin, 100 /ig/ml streptomycin and 5% FCS (complete medium) in the presence of 100 /ig/ml OVA. Starting day 3 cells were subcultured in complete medium containing 2.5% 24 h culture supernatant Lewis rat spleen cells (5 x 10^/ml) stimulated with concanavalin A (10 ^g/ml; Sigma, St Louis, USA) (Con A SN). Cells were cloned by limiting dilution in the presence of 5 x 10 s per well irradiated thymocytes (200 rad), 50 /ig/ml OVA and 2.5% Con A SN. Serial re-stimulations were performed every 30 days using 2x 10 s T cells per well and 3 x 10 6 irradiated thymocytes per well in the presence of 50 /tg/ml OVA, alternating with subculture in the presence of 2.5% Con A SN.
The isolation, maintenance and properties of the encephalitogenicTcell lineZia, reactive with the 72-85 sequence of MBP, has been previously described (32) . The isolation, maintenance and properties of the A2b helper T cell clone, reactive with the 180-188 amino acid sequence of mycobacterial hsp65, has been previously described (10) . Briefly, the rat T cell lines were cyclically re-stimulated in vitro for 3-4 days with irradiated (3000 rad) thymocytes as antigen presenting cells (APC) and 10 /ig/ml MBP for line Z1a or 10 ^g/ml heat-killed M. tuberculosis for clone A2b and propagated for 6 or 7 days in Iscove's modified Dulbecco's medium (Gibco Laboratories, Grand Island, NY), supplemented with 10% FCS, 10% EL-4 supernatant (as IL-2 source), 2 mM L-glutamine, 2-mercaptoethanol, antibiotics and 1 % non-essential amino acids. The generation, maintenance and characteristics of the IBV specific mouse T cell hybridoma MJB 100 is described elsewhere (33) . They were cultured in Iscove' modified Dulbecco's medium (Gibco), supplemented with 10% FCS, 2 mM L-glutamine, 2-mercaptoethanol and antibiotics.
Cell culture for the production of MHC For bulk culture, the rat T cell line Z1a was re-stimulated with 2.5 /tg/ml Con A in the above described culture medium supplemented with 5% FCS for 3-4 days and propagated in culture medium supplemented with 5% FCS and 10% EL4 supernatant for 6-7 days. The H-2 cf mouse B cell lymphoma cells, A20, were cultured in RPMI 1640 medium (Gibco) supplemented with 2 mM L-glutamine and 10% heat inactivated FCS.
Affinity purification of MHC molecules
Rat RT1 .B' was purified from cell lysates of Z1a T cell line. This line expresses MHC class II products: de novo synthesis has been established by metabolic cell labelling and subsequent immunoprecipitation (M. H. M. Wauben, unpublished data). Mouse I-E d was purified from cell lysates of A20 B cell lymphoma cells. Cells were lysed at 10 s cells/ml in PBS containing 1% NP-40, 25 mM iodoacetamide, 5 mM sodium orthovanadate and 0.5 mM phenylmethylsulfonyl fluoride. The lysates were cleared by centrifugation at 10,000 g for 20 min and subsequent passage over a 45 ^m filter (Millipore, Bedford, USA). RT-1 B 1 and I-E d molecules were purified using the mAb OX6 and 14-4-4S respectively, coupled to CNBr-activated Sepharose-4B (Pharmacia-LKB, Uppsala, Sweden). The cell lysates were passed over the columns, which were washed with 20 column volumes of PBS containing 0.1% SDS, 0.5% NP-40, three column volumes PBS containing 0.05% NP-40 and finally three column volumes of PBS containing 1% n-octyl glucoside (OG). The MHC molecules were eluted with 0.05 M diethylamine in 0.15 M NaCI containing 1% OG (pH 11). The eluate was immediately neutralized wtth 50 /J/ml 2 M Tris-HCI, pH 6.3, and concentrated by vacuum dialysis. MHC preparations were kept in PBS, 1% OG and 0.1% azide.
Biotinylation of marker peptides
Peptides MBP 72-85 and IBV 67-83 were biotinylated with NHS-LC-Biotin (Pierce, Rockford, USA). Biotin was dissolved in double distilled water (1 mg/100 /if) and added in 2-fold molar excess to peptide dissolved in 0.5 M NaHCO 3 , pH 9.0. After 2 h on be, 2 M Tris-HCI buffer, pH 6.3, was added at 10% of the total volume to prevent unwanted reactivity of the remaining biotin. The protocol resulted in -70% biotinylation of the peptide as estimated by ninhydrin reaction.
Peptides were biotinylated at higher ratio's in DMF. Thus we achieved higher labelling efficiency (up to 95%), but this did not result in improved signals upon testing in the binding assay.
MHC class II-peptide binding assay
Purified class II molecules (2-3 /xM) were incubated with 5 -500 nM of biotinylated peptides at pH 5 in a total volume of 15 fi\ for 48 h at room temperature in the presence of a protease inhibitor cocktail (final concentration 1 mM phenylmethylsulfonyl fluoride, 135 /*M A/-a-p-tosy1-L-lysine chloromethyl ketone, 142 /iM L-p-tosyiamino-2-phenylethyl chloromethyl ketone, 1 mM W-ethyl maleimide, 8 mM EDTA, 1.3 mM 1,10-phenanthroline and 73 /*M pepstatin A) and a final detergent concentration of 0.05% NP-40. The amount of MHC used appears appropriate since it is in the expected range known from mouse and human MHC studies using the radiolabelled peptide based assays (34, 35) . Since we have not actually defined the K d values of the different rat MHC -peptide combinations, nor the active part of the purified MHC, this conclusion remains a tentative one. However, we have tested a dose range of MHC (1-4 /iM) and found that in the competition assay optimal results were achieved with 3 /M of MHC. All binding studies were routinely performed at pH 5. For a largely qualitative assay such as ours, this pH was considered most appropriate (34) (35) (36) . For competition studies concentrations of up to 100 nM of biotinylated peptide were used in combination with 0-100 /iM of non-labelled competitor peptide.
The MHC -peptide mixtures were analyzed by SDS -PAGE under non-reducing conditions with the Laemmli buffer modified to a final SDS concentration of 0.1%, a slightly modified version from that employed by Jardetzky et al. (37) . The proteins were blotted onto nitrocellulose (Hybond-ECL; Amersham, Amersham, UK) using a semi-dry blotting system. After 1 h blocking with 5% dried milk in PBS -0.05% Tween 20, the blot was incubated for 45 min with biotinylated streptavidin -horseradish peroxidase complexes in a 1:1000 dilution (Amersham). Detection of the bbtjnytated peptides was done by enhanced chemiluminescence using the Western blot ECL kit (Amersham). Blots were exposed for 1 h on preflashed Hyperfilm -ECL (Amersham).
An image processing technique was developed to quantify the results of the electrophoresis/blotting experiments (manuscript in preparation). Briefly, the autoradiograph was recorded with a videocamera (MO High Resolution CCD; High Technology Holland BV, Eindhoven, The Netherlands) and digitized by a frame-grabber (PC Vision Plus; Image Technology USA., Worburn, MA). The digitized picture was processed and analyzed using the computer program TIM (version 3.20; Difa Measuring Systems, TEA, Breda, The Netherlands). The spots on the autoradiograph were quantified by multiplying the density of the pixels constituting the spots with the surface of the spots. Results were expressed as spot intensity [= pixel 2 x (standard maximum grey value -mean grey value of the spot)]. Inhibition curves were generated from these results and the concentration of competitor peptide at which 50% inhibition was achieved (ICso value) was extrapolated from these curves. Subsequently, these figures were converted into plusses to reflect the largely qualitative nature of the assay and the peptides were ranked with regard to their relative binding affinity for the RT1 .B 1 molecule.
Functional competition assay
Competition assays were done both with fixed and non-fixed APC. For fixed APC rat thymocytes or mouse A20 B lymphoma cells were fixed in 0.5% gluterakdehyde and subsequently pulsed for 3 h at pH 5 with a dose range of competitor peptide and a fixed, suboptimal concentration of stimulatory peptide (OVA 323-339Y, MBP 72-85 or IBV 67-83) in the presence of a protease inhibitor mix (composition and concentration as above). After extensive washing, antigen specific T cells (1/C11 ,P7 or Z1a) or hybridoma cells (MJB100) were added. 
Results
Detecting peptide -MHC class II interaction by chemiluminescence
As ligands for each of the two MHC molecules used to establish the assay, RT1. background signal (lanes c). The allele specificity of peptide binding could potentially be changed by the biotinylation. To exclude this possibility for each of the two peptide-MHC combinations in questions, we used a dose range of non-labelled MBP 72-85 or IBV 67-83 to inhibit the binding of either biotinylated IBV 67-83 to I-E d or biotinylated MBP 72-85 to RT1 ,B' respectively. In both cases the signal was not inhibited, thus confirming that the non-biotinylated peptides did not bind to the non-relevant MHC type either (data not shown).
The possible effect of biotinylation on the binding affinity of peptides for MHC is still of concern. Once a biotinylated peptide has been shown to bind to the MHC class II molecule in question in an allele specific manner then the assay can be converted into a competition assay. Such a competition assay measuring the ability of non-labelled peptides to block the binding of the biotinylated peptide to the MHC class II molecule will be independent of the effect of biotinylation The low concentration of marker peptides required to obtain a clear chemiluminescence signal enabled us to assess the binding capacity of non-labelled peptides by competition. We performed competition studies with the known strong I-E d binders DYN 1 -13 and HEL 107-116 as non-biotinylated competitor peptides. DYN 1 -13 is known to bind with higher affinity to I-E d than HEL 107-116 (26) . In agreement herewith we here show that the non-labelled DYN 1-13 inhibited the binding of biotinylated IBV 67-83 binding to I-E d at a lower concentration than non-labelled HEL 107-116 did (see Fig. 2 ). To further quantify the results a digitized picture of the autoradiographs was made. A resolution was achieved of 512 x 512 pixels and a maximum grey value number of 256. This extends beyond the resolution of the human vision. For each of the competitor peptides, a dose -response curve was made and from this the concentration at which 50% inhibition was reached was extrapolated. For DYN 1 -13 this dose was 2 /iM, whereas for HEL 107 -116 the dose was -5 /tM (Fig. 3) The inhibition curves were reproducible from gel to gel
Comparison of the biochemical competition assay with a functional competition assay
The biochemical assay was further confirmed by comparing it with a functional inhibition study in which fixed A20 cells were incubated with IBV 67-83 and competitor peptide at pH 5 in the presence of a protease inhibitor cocktail. The responses of the IBV 67-83 specific, I-E d restricted T hybridoma cells were used to measure the inhibitory activity of the two competitor peptides DYN 1-13 and HEL 107-166 (Fig. 4) . DYN 1-13 blocked the response by 50% at -70 /iM, whereas HEL 107-116 blocked the response by 50% at -175 /tM, thus showing that the biochemical binding assay yields similar results as the T cell functional competition assay
Peptide binding to the rat RT1 0
We now assessed the relative MHC class II binding affinity of peptides relevant for the four autoimmune disease models in the Lewis rat, their analogues and a single non-disease related peptide (OVA 323 -339). T cell responses have been identified as being RT1.B 1 restricted for all the peptides tested (20) (21) (22) (23) (24) (25) , with the exception of the response to the MBP 87 -99 which is D-locus restricted (22) . A dose range of non-labelled peptides was incubated together with 100 nM of biotinylated MBP 72 -85 and 3 )M of affinity purified RT1.B 1 at pH 5, and the resulting binding determined as described above. The degree of inhibition was further quantified by image processing. From the dose -response curves obtained for each of the peptides the concentration at which 50% inhibition was achieved was extrapolated. The peptides could be ranked into five broadly defined categories. dominant epitopes from guinea pig and rat, a guinea pig MBP 72-85 alanine substitution analogue (VBJ-A), and the natural hsp65 178 -186 and 180 -188 sequences recognized by the athritogenic T cell clone A2b. Notably, among the poor binders (+, with \C X values of 100 -300 /iM) were the IRBP 579 -591 peptide, inducing uveitogenic activity in IRBP sensitized T cells, and the guinea pig MPB 53-67 peptide, comprising a secondary EAE associated epitope; the uveitogenic IRBP 1181 -1191 peptide and the immunodominant EAMG associated AChR 101 -116 peptide were found to be very poor binders ( + /-), even at 256 pM not more than a slight inhibition was observed. Also, two alanine substitution analogues, hsp65 180-188L 18S -A and MBP 72-85Ea2-A, were found to be poor binders. As expected, no inhibition was observed for the secondary rat MBP 87 -99 epitope from which it is known that "Inhibition of the binding of 100 nM biotinytated MBP 72-85 to 3/iM of affinity purified RT1.B A selected subset of the peptides was tested in functional competition assays to confirm the immunological relevancy of the direct binding data and to compare this assay to the functional competition assay. The functional assay was performed with either fixed or non-fixed APC, the former at pH 5 and in the presence of a protease inhibitor mix. Results are shown in Table 2 . The concentration of competitor peptide needed to obtain 50% inhibition (ICBQ) was compared with the ICSQ of an arbitrarily chosen standard competitor peptide. This relative inhibitory concentration can be used to make comparisons between different T cell read-outs. The non-analogous OVAspecific, RT1 .B' restricted T cell read-out was used to assess the in vitro competitor function of the two strongest binders MBP72-85D 81 -Aand hsp65 180-188L 183 -A. Using either of the two functional competition assays (fixed or non-fixed APC) the results confirmed the earlier biochemical findings that MBP 72-85D 81 -A is a better RT1.B 1 binder than hsp65 180-188L 183 -A. Similar relative ICSQ for the MBP 72-85D 81 -A and hsp65 180-188L 183 -A binding to RT1.B' binding were obtained using the MBP 72-85 specific, RT1.B 1 restricted Z1a T cells for the functional read-out. In contrast, using the hsp 180-188 specific, RT1.B 1 restricted T cell clone, A2b, it was shown that within the given experimental design the IC50 value 
Discussion
The modulation of autoimmune disease by interfering with the CD4 + T help response through MHC blockade is a novel approach. It has recently been observed that in vivo T cell activation can be prevented by co-immunization with stimulator peptide and MHC binding competitor peptides (8) . Successful attempts to interfere with the onset or occurrence of autoimmune diseases by immunization with non-pathogenic competitor peptides have been achieved in the rodent EAE model (13) (14) (15) (16) . The Lewis rat presents an ideal model species for studying autoimmune diseases since a number of experimental autoimmune diseases can be induced in this rat strain. Disease associated T cell determinants in the Lewis rat have been defined for most models (17) (18) (19) (20) (21) (22) 26) and, with a single exception, the different autoimmune T cell responses are restricted to the same MHC class II specificity, RT1 .B 1 . The same competitor peptide specific for RT1.B 1 can therefore be studied in several different autoimmune diseases models in the same experimental animal strain. However, to identify such RT1.B 1 binding competitor peptides and to understand the possible mechanism of action it becomes essential to measure directty the binding of competitor peptides to MHC class II molecules as well as the binding of peptides involved in activating autoreactive T cell responses.
Our currently used method employs the detection of biotinylated peptides by chemiluminescence, whereby we have achieved stable and non-reactive labelling of peptides, yet maintained the required sensitivity. The assay has been established for both the mouse I-E d and the rat RT1.B
1
. The results obtained show sensitive and allele-specific binding. The method enables competition studies in which the relative binding affinities of a set of non-labelled peptides can be easily assessed. The assay is thus especially useful for the screening of sets of peptides, looking for good binders, in its present form it is less well suited for kinetic studies. A particular asset of the analysis is that it solves the problem of high non-specific backgrounds observed for some peptides in the gel filtration analysis, due to aggregation of peptide molecules. When starting with a not yet tested MHC specificity this can severely hamper the search for good binders. The high separation power of the SDS-PAGE analysis circumvents this problem. Furthermore, the sensitivity of our test system is high allowing the use of very low concentrations of labelled marker peptide, comparable to what is used in peptide binding assays based on radiolabelled peptides (34, 35) . This is in contrast to the high concentrations of labelled peptide necessary to detect binding of biotin labelled peptide to whole cells and detected by FACS analysis (38,39 and M. H. M. Wauben etal., unpublished results). The very high concentration of labelled peptides needed to perform the direct binding assay based on FACS analysis makes it difficult to convert the assay into the versatile competition assay, something which can reliably be achieved with the present assay. Recently, potentially very useful biotin based assays have been developed (40 -42) . It should be noted, however, that the successful outcome of these latter assays is in part dependent on the particular combination of MHC specificity and anti-class II mAb. To be more specific, the conformational binding properties of the mAb and MHC molecules can interfere in the measurements of MHC -peptide complex formation. In a species like the rat where a very limited choice of mAb is available, this could seriously hinder the development of a binding assay. In our present study this is of no concern.
The results obtained with the biochemical competition assay were confirmed by functional competition assay for both the mouse and the rat systems. It is obvious that the ability to inhibit MHC binding and subsequently inhibit specific T cell stimulation varies greatly from peptide to peptide. The direct binding assay will yield information which is important in the generation of a MHC blocking strategy.
With respect to the relative binding affinity of the autoimmune associated determinants it is of interest to note that, firstly, none of the natural sequences from autoimmune disease associated proteins were among the highest binders (1 -10 /*M range). Secondly, from the peptides with direct disease inducing potential, the guinea pig MBP 72-85 peptide and the IRBP 1181-1191 peptide, the MBP peptide was found to be a high 'intermediate' binder, as opposed to the IRBP peptide, which was a very poor binder. Also the immunodominant AChR epitope and the secundary IRBP and MBE epitopes were found to be poor binders. Notwithstanding their apparent poor binding affinity, these peptides have the potential to play crucial roles in the development of the disease (20, 22, 24) . It was argued by Lamont etal. (43) and Wall etal. (44) that in the mouse EAE model MHC binding affinity is correlated with encephalitogenicity and that a high MHC binding affinity may be a necessary characteristic of an encephaiitogenic determinant. In our study it appears that in the Lewis rat the major encephaiitogenic determinants are intermediary binders, i.e. ~ 10-fold less effective than the highest binder, the non-autoimmune disease related OVA peptide. Furthermore, a substitution analog of MBP 72-85 with about tenfold increased MHC binding affinity (MBP72-85ST9-A) and capable of inducing disease did not show an increased encephaiitogenic potential as compared to the natural sequence (M. H. M. Wauben etal., submitted for publication), suggesting that at least in this model high MHC binding affinity is not directly correlated with disease inducing potential. The finding that the natural peptide sequences relevant for the AA, EAU and EAMG models were low-intermediates to poor binders, is more in line with the work of Gammon and Sercarz (45) , in which it is hypothesized that pathogenic determinants on self antigens resemble so-called minor determinants and are poorty presented, resulting in the evasion of tolerance induction by T cells with specificity for these determinants. In view of the results from the mouse EAE model (43, 44) , it is of importance to establish to what degree this concept is dependent on the particular disease and/or self antigen involved. Consequently, we are currently in the process of extending our panel of autoimmune disease related and non-related peptides, to be tested in the direct MHC binding assay.
By generating single amino acid substitution analogues of disease associated T cell determinants we were able to define peptides with improved MHC binding affinity, to be used for blocking purposes. The now apparent relative intermediate to poor binding affinity of the disease associated peptides has supported and facilitated this approach. An alternative strategy using analogues involves engagement without stimulation of the TCR (9) . An example of this may be the strong inhibitory in vitro (tested in an analogous system) and in vivo capacity of hsp65 180-188L 183 -A (16), which cannot be based on MHC blockade alone since in the direct binding assay as well as in the non-analogous functional assay, MBP72-85D 81 -A was shown to have a higher affinity for MHC. In conclusion, this rat MHC-peptide binding assay may prove very valuable in the search for competitors of the formation of the trimolecular T cell stimulatory complex.
